Vitamin D binding protein and monocyte response to 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D: analysis by mathematical modeling. by Chun, Rene F et al.
UCLA
UCLA Previously Published Works
Title
Vitamin D binding protein and monocyte response to 25-hydroxyvitamin D and 1,25-
dihydroxyvitamin D: analysis by mathematical modeling.
Permalink
https://escholarship.org/uc/item/9w597237
Journal
PloS one, 7(1)
ISSN
1932-6203
Authors
Chun, Rene F
Peercy, Bradford E
Adams, John S
et al.
Publication Date
2012-01-24
DOI
10.1371/journal.pone.0030773
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Vitamin D Binding Protein and Monocyte Response to
25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D:
Analysis by Mathematical Modeling
Rene F. Chun1*, Bradford E. Peercy2, John S. Adams1,3, Martin Hewison1,3
1UCLA and Orthopaedic Hospital, Department of Orthopaedic Surgery and Orthopaedic Hospital Research Center, Los Angeles, California, United States of America,
2Department of Mathematics and Statistics, University of Maryland, Baltimore County, Baltimore, Maryland, United States of America, 3Molecular Biology Institute,
University of California Los Angeles, Los Angeles, California, United States of America
Abstract
Vitamin D binding protein (DBP) plays a key role in the bioavailability of active 1,25-dihydroxyvitamin D (1,25(OH)2D) and its
precursor 25-hydroxyvitamin D (25OHD), but accurate analysis of DBP-bound and free 25OHD and 1,25(OH)2D is difficult. To
address this, two new mathematical models were developed to estimate: 1) serum levels of free 25OHD/1,25(OH)2D based
on DBP concentration and genotype; 2) the impact of DBP on the biological activity of 25OHD/1,25(OH)2D in vivo. The initial
extracellular steady state (eSS) model predicted that 50 nM 25OHD and 100 pM 1,25(OH)2D), ,0.1% 25OHD and ,1.5%
1,25(OH)2D are ‘free’ in vivo. However, for any given concentration of total 25OHD, levels of free 25OHD are higher for low
affinity versus high affinity forms of DBP. The eSS model was then combined with an intracellular (iSS) model that
incorporated conversion of 25OHD to 1,25(OH)2D via the enzyme CYP27B1, as well as binding of 1,25(OH)2D to the vitamin
D receptor (VDR). The iSS model was optimized to 25OHD/1,25(OH)2D-mediated in vitro dose-responsive induction of the
vitamin D target gene cathelicidin (CAMP) in human monocytes. The iSS model was then used to predict vitamin D activity
in vivo (100% serum). The predicted induction of CAMP in vivo was minimal at basal settings but increased with enhanced
expression of VDR (5-fold) and CYP27B1 (10-fold). Consistent with the eSS model, the iSS model predicted stronger
responses to 25OHD for low affinity forms of DBP. Finally, the iSS model was used to compare the efficiency of
endogenously synthesized versus exogenously added 1,25(OH)2D. Data strongly support the endogenous model as the
most viable mode for CAMP induction by vitamin D in vivo. These novel mathematical models underline the importance of
DBP as a determinant of vitamin D ‘status’ in vivo, with future implications for clinical studies of vitamin D status and
supplementation.
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Introduction
In recent years there has been a surge of interest in vitamin D
and its wide-ranging health benefits. This is due, in part, to the
many association studies linking vitamin D status with common
human diseases [1,2]. However, another key factor that has
influence our current view of vitamin D and human health has
been the reappraisal of vitamin D physiology that has taken place
over the last five years [2]. Two pivotal concepts are central to our
new perspective on vitamin D: 1) it is now clear that sub-optimal
vitamin D status or vitamin D insufficiency is a prevalent health
problem across the globe [1]; and 2) vitamin D is a potent
modulator of biological responses that extend far beyond its
traditional effects on calcium homeostasis and bone metabolism
[3,4,5,6].
This new perspective on vitamin D is highly dependent on
analysis of serum concentrations of 25-hydroxyvitamin D
(25OHD), which is considered to be the most dependable marker
of vitamin D status in any given individual [7]. Serum 25OHD
levels have been used widely in disease association studies but the
precise values that define vitamin D-sufficiency and insufficiency
remain controversial [8]. In this study we have investigated
another component of the vitamin D system that further
complicates the analysis of vitamin D status, namely the serum
vitamin D binding protein (DBP). DBP is the main serum carrier
of vitamin D metabolites with albumin acting as an alternative
lower affinity binder [9,10]. DBP exists in three major polymor-
phic forms, yielding six allelic combinations that occur at different
frequencies among ethnic groups [11]. The different allelic forms
of DBP circulate at varying concentrations [12], and exhibit
different binding affinities for 25OHD and 1,25(OH)2D [13]. Both
of these variables have the potential to influence the bioavailability
of vitamin D, with recent studies suggesting that some functions of
vitamin D correlate more closely with levels of ‘free’ 25OHD
rather than the total serum concentrations of this metabolite [14].
In addition to its transport function, DBP also plays a key role in
the endocrine synthesis of 1,25(OH)2D within renal proximal
tubules, where 25OHD bound to DBP is actively recovered from
glomerular filtrate via megalin-mediated receptor endocytosis
[15]. This mechanism fuels the metabolism of 25OHD by kidney
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cells expressing the vitamin D-activating enzyme 25-hydroxyvita-
min D-1a-hydroxylase (CYP27B1) but also acts to maintain serum
levels of 25OHD. In contrast to its actions in the kidney, the role of
DBP as a mediator of vitamin D metabolism and function in other
target cells remains far less clear, despite the fact that CYP27B1
expression has been described for a wide range of extra-renal
tissues [16]. Data from our group have shown that local intracrine
conversion of 25OHD to 1,25(OH)2D in monocytes expressing
CYP27B1 and the vitamin D receptor (VDR) is a key mechanism
underpinning innate antibacterial responses [17]. The efficacy of
this activity is highly dependent on the availability of substrate for
CYP27B1, namely serum levels of 25OHD [17,18]. However,
studies in vitro have shown that 25OHD-induced monocyte-
macrophage antibacterial activity is attenuated by the presence of
DBP, with this effect being most pronounced with high affinity
forms of DBP [19]. Similar effects have also been demonstrated in
keratinocytes for 1,25(OH)2D induced responses [20]. The
conclusion from these studies is that non-classical target cells for
vitamin D such as monocytes-macrophages are dependent on
‘free’, rather than DBP-bound vitamin D ligands. This supports
the so-called ‘free hormone hypothesis’ for the action of steroid
hormones in general [21] but also suggests that the definition of
vitamin D status cannot simply be defined by total serum levels of
25OHD.
In the current study, we have explored further the importance
of DBP as a determinant of free vitamin D and vitamin D
function. Given that physical analysis of free levels of 25OHD or
1,25(OH)2D in serum is extremely difficult, we have used a
mathematical extra-cellular steady state (eSS) model to estimate
free levels of these metabolites based on concentration and
genotype-defined variations in DBP affinity. The eSS model was
then extended to assess the impact of DBP on intracellular
responses to 25OHD and 1,25(OH)2D, using an intracellular
steady state (iSS) model validated by in vitro dose-response studies
with adherent monocytes-macrophages. Using this approach, we
projected the effects of DBP genotype/affinity on non-classical
responses to vitamin D in vivo. This DBP mathematical model
provides an important new tool for further analysis of the cellular
actions of vitamin D but may also help to redefine parameters for
vitamin D status used in clinical studies.
Results
A mathematical model for estimation of ‘free’ 25OHD
and 1,25(OH)2D based on DBP concentration and affinity
Previous studies have described mathematical models to
estimate serum levels of ‘free’ (unbound) 25OHD and
1,25(OH)2D, based on two-ligand-two-binding protein ‘steady-
state’ parameters [10,22,23] (Figure 1 dark text and arrows). In
each case, these models utilized a single binding coefficient for
DBP binding of 25OHD and 1,25(OH)2D. However, this does not
reflect the natural variations in DBP binding affinity that occur as
a consequence of group-specific component (GC) allelic inheri-
tance (Table 1). Therefore, we generated a new model for
determining free vitamin D metabolites that incorporated DBP
affinity coefficients for the six different GC allele combinations
described in Table 1. The resulting eSS model was used to predict
levels of free 25OHD and 1,25(OH)2D in vitro (5% serum)
(Figure 2A and 2B) and in vivo (100% serum) (Figure 2C and 2D).
In each case, an appropriate concentration of serum DBP and
albumin was assigned to each in vitro or in vivo condition and
genotype combination. Likewise, levels of 25OHD (2.5 nM in vitro
and 50 nM in vivo) and 1,25(OH)2D (5 pM in vitro and 100 pM in
vivo) were fixed when concentrations of the other metabolite
varied. Data showed that for a physiological level of serum
25OHD (50 nM), the percentage of free 25OHD varied between
0.5–1.5% in vitro, and 0.026–0.074% in vivo depending on DBP
genotype. For a physiological level of 1,25(OH)2D (100 pM), the
level of free 1,25(OH)2D varied between 7.5–22% in vitro, and 0.4–
1.3% in vivo. In each case, the highest level of free 25OHD or
1,25(OH)2D was observed for the GC allelic combination with the
lowest binding affinity, GC2/2. To further illustrate the impact of
DBP genotype on levels of free 25OHD in vivo, data were
generated for each combination of GC alleles under conditions of
vitamin D-deficiency (25 nM total 25OHD), -sufficiency (50 nM
25OHD) and enhanced-sufficiency (100 nM 25OHD). Results in
Table 2 showed a sustained 3-fold difference in free levels of
25OHD for low affinity GC2-2 DBP versus GC1F-1F DBP across
the spectrum of vitamin D status.
A mathematical model for estimation of intracellular
responses to 25OHD and 1,25(OH)2D
The potential importance of free 25OHD as a measurement of
the bioavailability and function of this metabolite has been
highlighted by recent studies of skeletal homeostasis [14], a
classical function of vitamin D. Additionally, data from our group
indicate that free 25OHD may also be the key determinant of non-
classical responses to vitamin D [19]. Therefore, to assess the
biological impact of free 25OHD and 1,25(OH)2D, we extended
the mathematical modeling derived from the initial DBP/albumin
binding coefficients (eSS model) to include parameters for 25OHD
metabolism and 1,25(OH)2D receptor binding (Figure 1 gray text
and arrows). The resulting intracellular iSS model incorporated
the following considerations: 1) movement of vitamin D
metabolites from the extracellular space into intracellular fluid;
2) enzymatic conversion of 25OHD into 1,25(OH)2D via the
enzyme CYP27B1; 3) binding of 25OHD and 1,25(OH)2D to
Figure 1. Schematic framework of parameters used to produce
extracellular steady state (eSS) and intracellular (iSS) mathe-
matical models for vitamin D metabolism and function. Free
25OHD and 1,25(OH)2D interacting with extra-cellular vitamin D binding
protein (DBP) or albumin indicated in black text and arrows (eSS
model). Intra-cellular interactions involving the vitamin D-activating
enzyme (CYP27B1), the vitamin D receptor (VDR) and transcriptional
induction of the antibacterial protein CAMP via interaction between
VDR and the CAMP gene promoter (CAMP-DNA) indicated by grey text
and arrows (iSS model).
doi:10.1371/journal.pone.0030773.g001
Vitamin D Math Modeling
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e30773
Table 1. Binding protein and ligand biochemical parameters for eSS mathematical model.
Average human serum levels [23] Association constants (Ka) [9,10]
DBP (mixed) 5.0 mM DBP for 25OHD 76108 M21
Albumin 650 mM DBP for 1,25(OH)2D 4610
7 M21
25OHD 50 nM Albumin for 25OHD 66105 M21
1,25(OH)2D 0.1 nM Albumin for 1,25(OH)2D 5.4610
4 M21
DBP concentration
by genotype (average) [12] Relative affinity [13] 25OHD 1,25(OH)2D
GC1F/1F 5.17 mM GC1F 1.000 1.000
GC1F/1S 5.15 mM GC1S 0.536 0.356
GC1S/1S 5.27 mM GC2 0.321 0.233
GC1F/2 4.77 mM
GC1S/2 4.79 mM
GC2/2 4.35 mM
doi:10.1371/journal.pone.0030773.t001
Figure 2. Effects of DBP genotype on free 25OHD and 1,25(OH)2D in vitro and in vivo. eSS-predicted levels of free 25OHD and 1,25(OH)2D
relative to total serum levels of these metabolites for in vitro tissue culture conditions (5% serum) and in vivo (100% serum) according to DBP
genotype (GC allele combinations). X-axis indicates total serum concentrations of 25OHD (nM) or 1,25(OH)2D (pM) and Y-axis indicates concentration
of free 25OHD or 1,25(OH)2D. Concentration of (A) 1,25(OH)2D= 5 pM (5% serum), (B) 25OHD=2.5 nM (5% serum), (C) 1,25(OH)2D=100 pM (100%
serum) or (D) 25OHD=50 nM (100% serum) were fixed.
doi:10.1371/journal.pone.0030773.g002
Vitamin D Math Modeling
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vitamin D receptor (VDR); and 4) liganded-VDR binding to
vitamin D response elements in target gene promoters, leading to
active transcription. Table 3 and 4 provide a brief description of
the variables and parameters used in the models. The mathemat-
ical equations used to express the relationships outlined in the full
Figure 1 (eSS and iSS models) are described in the Mathematical
Modeling subsection of Material and Methods along with more
detailed justifications for parameters.
The development of the iSS model was based on data from in
vitro (5% human serum) analysis of the dose-responsive effects of
25OHD and 1,25(OH)2D on monocyte expression of mRNA for
the antibacterial protein cathelicidin (CAMP). Initial analysis using
the iSS model was based on a single DBP genotype (GC1F/1F) at
a fixed concentration of 0.25 mM (5% serum). The resultant
modeling is shown in Figure 3. The experimental data from the in
vitro dose-response study is represented by the blue dots while the
black lines represent the values predicted by the iSS model. Based
on these observations, the iSS model was then used to predict the
induction of monocyte-macrophage CAMP by 25OHD in vivo
relative to vitamin D status (deficiency [25 nM 25OHD],
sufficiency [50 nM 25OHD], and higher sufficiency [100 nM
25OHD]) and DBP genotype (using corresponding affinity
constants [Table 1]) and raising the concentrations of DBP and
albumin from 5% serum to 100% serum conditions. The resulting
data (Table 5), indicate that under the same basal conditions used
for in vitro data in Figure 3, the iSS model predicts only a minimal
induction of in vivo CAMP expression, with this being unaffected
by DBP genotype. We have shown previously that vitamin D-
mediated induction of monocyte CAMP is potently enhanced
following the induction of CYP27B1 and VDR by pathogen-
associated molecular patterns (PAMPs) such as 19 kDa lipoprotein
(toll-like receptor [TLR]2 ligand) or lipopolysaccharide (TLR4
ligand) [17,18]. Therefore, additional iSS data were generated
incorporating a 5-fold induction of VDR and a 10-fold induction
of CYP27B1 expression, similar to those described in other studies
[24,25]. Under these conditions of VDR/CYP27B1 activation, the
iSS model predicted a 3- to 7-fold induction of CAMP at 50 nM
25OHD for low affinity forms of DBP (GC1S/2 or GC2/2), with
this increasing to 20–40-fold at 100 nM 25OHD. By contrast, for
high affinity forms of DBP (GC1F/1F) the predicted induction of
CAMP by 25OHD remained minimal even at levels of 25OHD
defined as vitamin D-sufficient (50 nM) (Table 5). For this
particular DBP genotype, a meaningful rise in CAMP induction
was only observed at 100 nM serum 25OHD.
The adaptability of the mathematical model was tested relative
to in vitro induction of the osteocalcin gene in MG-63 human
osteoblastic bone cells (see file Text S1). After incubation for 6 hrs
in media containing 2% serum with doses of 25OHD (0–200 nM)
or 1,25(OH)2D (0–20 nM), RNA was isolated, cDNA synthesized
and osteocalcin expression (DDCt) determined by qPCR (Figure
S1). The dashed lines indicate data produced by the iSS
mathematical model using monocyte parameters. Given the
different cellular context and kinetics of activating a different
gene, not surprisingly, the data generated by the monocyte model
parameters (dashed lines) did not match the experimental data for
osteoblastic cells (blue dots with error bars). Since 1,25(OH)2D
activation is mechanistically the most direct pathway of action,
parameters pertaining to 1,25(OH)2D interactions were modified
first. The less pronounced rise in osteocalcin expression in
response to escalating doses of 1,25(OH)2D strongly indicated
that MG63 cells were markedly less sensitive to 1,25(OH)2D
compared to adherent monocytes. Mathematically, this was most
effectively expressed with a reduction in Kr2, the affinity of VDR
for 1,25(OH)2D parameter. Adjustments in the Kcc2 (1,25(OH)2D/
VDR affinity for VDRE-DNA parameter), pp (cooperativity
constant of the Kr2 interaction) and VDR concentration refined
the model enabling fit to experimental data (Figure S1 dotted lines;
black line and dotted line are the same in panel B but not in panel
A). Subsequently, the 25OHD dose data were assessed. A change
in CYP27B1 concentration resulted in a fit with experimental data
(Figure S1 black lines). This fit could also be accomplished by
raising the CYP27B1 enzyme activity rate (Kcat) alone or by
combinations of increases in CYP27B1 concentration and activity
rate.
Table 2. Predicted impact of vitamin D status and DBP genotype (Gc allelic combinations) on free 25OHD as projected by eSS
model.
Vitamin D Vitamin D Vitamin D
Deficiency Sufficiency Sufficiency (higher)
Subject Total Free Total Free Total Free
Genotype 25OHD (nM) 25OHD (nM) 25OHD (nM) 25OHD (nM) 25OHD (nM) 25OHD (nM)
GC1F/1F 25 0.006 50 0.013 100 0.025
GC1F/1S 25 0.008 50 0.016 100 0.032
GC1F/2 25 0.010 50 0.019 100 0.039
GC1S/1S 25 0.011 50 0.021 100 0.043
GC1S/2 25 0.014 50 0.028 100 0.055
GC2/2 25 0.018 50 0.037 100 0.074
doi:10.1371/journal.pone.0030773.t002
Table 3. Variables for mathematical modeling.
Variable Symbol Variable Symbol
Free 25OHD (intracellular) v1
c VDR:25OHD complex r1
Free 25OHD (extracellular) v1
o VDR:1,25(OH)2D complex r2
Free 1,25(OH)2D (intracellular) v2
c CYP27B1:25OHD Y1
Free 1,25(OH)2D (extracellular) v2
o Transactivation signal CAMP
Total VDR RT VDRE activated by r1 o1
Total CYP27B1 YT VDRE activated by r2 o2
doi:10.1371/journal.pone.0030773.t003
Vitamin D Math Modeling
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Use of the iSS mathematical model to assess the relative
importance of intracrine versus endocrine action of
vitamin D in vivo
1,25(OH)2D has the potential to act in both an endocrine and
intracrine manner. Circulating levels of 1,25(OH)2D generated via
the kidneys appear to play a key role in the classical calciotropic
actions of the endocrine vitamin D system [2]. By contrast,
intracrine, cell-specific conversion of 25OHD to 1,25(OH)2D
appears to be the most likely mechanism for non-classical actions
of vitamin D on cells such as monocytes-macrophages [26]. To
investigate the validity of this latter assumption, the iSS model was
used to assess the relative impact of 25OHD or 1,25(OH)2D as
inducers of monocyte CAMP in vivo (Table 6). An exclusive
intracrine mechanism was assessed by eliminating serum
1,25(OH)2D and clamping serum 25OHD at a sufficiency level
of 50 nM. An exclusive endocrine mechanism was assessed by
eliminating serum 25OHD and clamping serum 1,25(OH)2D at a
level of 100 pM. In a basal, unstimulated state, both intracrine and
endocrine mechanisms predict minimal induction of monocyte-
macrophage CAMP. Likewise, in an ‘activation’ setting with
elevated VDR and CYP27B1 endocrine induction of CAMP by
1,25(OH)2D was also predicted to be minimal. By contrast, under
Table 4. Parameters for iSS mathematical model.
Value (Unit) Function Rationale
d=6 (hr21) permeability of cells to free 25OHD or 1,25(OH)2D fit from i
Kr1 = 5610
22 (mM) rate constant v1
c binding to VDR ii
Kr2 = 1610
24 (mM) rate constant v2
c binding to VDR iii
Kcat = 1610
23 (hr21) activating constant for 25OHD:CYP27B1 iv
Km= 1 (mM) Michaelis constant for 25OHD binding to CYP27B1 v
YT = 3.0610
24 (mM) total concentration of CYP27B1 estimate & iv
g= 1 (mM) net CAMP production normalized
RT = 1.2610
23 (mM) concentration of VDR vi
Kcc1 = 1610
23 (mM) VDR:25OHD affinity for CAMP VDRE vii
Kcc2 = 1610
24 (mM) VDR:1,25(OH)2D affinity for CAMP VDRE viii & [44]
mm=1 (none) cooperativity constant for 25(OH)2D binding by VDR viii
pp = 2 (none) cooperativity constant for 1,25(OH)2D binding by VDR viii
m= 2 (none) cooperativity constant for VDRE binding by r1 viii
p = 2 (none) cooperativity constant for VDRE binding by r2 viii
i. rate has only been measured for 1,25(OH)2D [50].
ii. Kr1 = 500*Kr2.
iii. Kr2 = 1/Kd where Kd = 1610
210 [42].
iv. Kcat*YT = 0.1 mM/hr [46].
v. estimate based on [29,47,48,49].
vi. 3000 molecules/cell [40] and spherical cell of 10 mm radius [41].
vii. Kcc1 = 10*Kcc2.
viii. fit to in vitro data.
doi:10.1371/journal.pone.0030773.t004
Figure 3. Comparison of iSS-predicted effects of 25OHD or 1,25(OH)2D on monocyte expression of CAMP with observed in vitro
responses of monocytes to treatment with these metabolites. Adherent human monocytes were incubated for 6 hrs in media containing 5%
serum with doses of (A) 25OHD (1–300 nM) and (B) 1,25(OH)2D (0.1–6 nM). The experimental data is indicated by blue dots and error bars (6 SD).
Black lines indicate data predicted by the iSS mathematical model assuming basal levels of VDR and CYP27B1 (i.e. no activation). For the purpose of
this modeling, DBP was represented by the GC1F/1F allelic combination.
doi:10.1371/journal.pone.0030773.g003
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conditions of VDR/CYP27B1 activation, the iSS model predicted
intracrine induction of CAMP by 25OHD, with this response
being most prominent with low affinity forms of DBP.
Discussion
Current guidelines for vitamin D-sufficiency published by the
Institute of Medicine are based exclusively on serum levels of
25OHD (50 nM) required for adequate bone health [8]. It is
unclear whether this target level will also be relevant to non-
classical responses to vitamin D, and findings from association
studies have led many researchers to propose a higher level of
serum 25OHD (75 nM) for vitamin D sufficiency [1,7]. In data
presented here we show that another important consideration is
the amount of 25OHD and/or 1,25(OH)2D that is actually
available for use within target tissues – in other words the amount
of these metabolites that is free from DBP binding.
The potential importance of free 25OHD as a determinant of
vitamin D function is illustrated by a recent study of the
relationship between serum 25OHD and skeletal health. In this
report the authors demonstrated association between bone mineral
density (BMD) and levels of free 25OHD but not total serum
25OHD [14]. The implication from these human data was that
levels of free 25OHD are a more meaningful marker of the
biological impact of vitamin D than total 25OHD. In this study
the authors also described association between BMD and
‘bioavailable’ 25OHD (free 25OHD combined with albumin
bound 25OHD). The distinction between these two parameters is
interesting but no significant difference was noted for associations
between free or ‘bioavailable’ 25OHD and BMD [14], possibly
because DBP is a relatively abundant steroid hormone binding
protein. Because of this, we did not conduct analysis using their
definition of ‘bioavailable’ vitamin D in the model we present in
this report. However, it is possible that bioavailability versus free
steroid may be informative for other steroid-binding globulins such
as sex-hormone binding globulin, which is approximately 100-fold
less abundant than DBP [27].
At present there is no available technology for rapid and
reproducible measurement of free vitamin D metabolites in serum
samples. Rather the studies linking free 25OHD with BMD for
example [14], relied on estimation of the level of free 25OHD
based on existing mathematical models. The eSS model presented
here was derived using the same equations employed to estimate
free vitamin D in the original studies of this concept [9,10], as well
as the recent BMD association data [14]. Values for free 25OHD
and 1,25(OH)2D generated by the new eSS models are consistent
with previous reports [9,10]. However, importantly, the new eSS
math model we report here incorporates not only DBP serum
concentration but also genotypic variations in DBP affinity. The
GC1S and GC2 alleles of the DBP gene are derived from the
ancestral GC1F allele following two amino acid changes: a D432E
change to form GC1S and a T436K change to form GC2. These
Table 5. Predicted effects of vitamin D status and DBP genotype (Gc allelic combinations) on in vivo monocyte expression of
CAMP under basal or immune activated conditions.
Deficiency Sufficiency Sufficiency (higher)
Subject 25 nM 25OHD (total) 50 nM 25OHD (total) 100 nM 25OHD (total)
Genotype Basal Activated Basal Activated Basal Activated
GC1F/1F 0.010 0.010 0.010 0.011 0.010 0.019
GC1F/1S 0.010 0.010 0.010 0.012 0.010 0.035
GC1F/2 0.010 0.011 0.010 0.015 0.010 0.062
GC1S/1S 0.010 0.011 0.010 0.019 0.010 0.090
GC1S/2 0.010 0.013 0.010 0.032 0.010 0.199
GC2/2 0.010 0.018 0.010 0.072 0.010 0.420
doi:10.1371/journal.pone.0030773.t005
Table 6. Predicted induction of monocyte expression of CAMP under endocrine (1,25(OH)2D only) or intracrine (25OHD only)
conditions with varying DBP genotype and levels of activation.
Both mechanisms Intracrine mechanism Endocrine mechanism
50 nM 25OHD 50 nM 25OHD 0 nM 25OHD
Subject 0.1 nM 1,25(OH)2D 0 nM 1,25(OH)2D 0.1 nM 1,25(OH)2D
Genotype Basal Activated Basal Activated Basal Activated
GC1F/1F 0.010 0.011 0.010 0.010 0.010 0.010
GC1F/1S 0.010 0.012 0.010 0.011 0.010 0.010
GC1F/2 0.010 0.015 0.010 0.012 0.010 0.010
GC1S/1S 0.010 0.019 0.010 0.013 0.010 0.010
GC1S/2 0.010 0.032 0.010 0.019 0.010 0.010
GC2/2 0.010 0.072 0.010 0.036 0.010 0.010
doi:10.1371/journal.pone.0030773.t006
Vitamin D Math Modeling
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amino acid changes correlate with decreased affinity of DBP for
vitamin D metabolites [13]. The elevated levels of free 25OHD
calculated for low affinity forms of DBP such as GC2/2 and
GC1S/2 therefore provide an explanation for the relative potency
of these forms of DBP in promoting antibacterial responses to
25OHD in vitro [19].
The eSS model for estimating free 25OHD is easily imple-
mented with the input of several variables (DBP genotype, DBP
concentration, albumin concentration, 25OHD and 1,25(OH)2D
levels). Since not all of these variables may be available for every
subject studied, the model can be used to generate a spectrum of
results. For example, in the case of absent DBP genotype, it is
possible to generate a range of free 25OHD values from lowest to
highest affinity forms of DBP. In the absence of data for serum
concentrations of 1,25(OH)2D (a non-routine assay), an optimized
input value (e.g. 100 pM 1,25(OH)2D) can be used instead.
However, analysis of the effects of variable levels of 1,25(OH)2D
suggest that this has very little impact on free 25OHD relative to
changes in DBP concentration or binding affinity (data not
shown). With these caveats in mind, the eSS model provides an
exciting new approach to assessing the true biological vitamin D
status of any given individual. Patients with low serum levels of
25OHD may nevertheless exhibit adequate or optimal levels of
free 25OHD if they have inherited a low affinity form of DBP. GC
allelic combinations such as Gc2/2 not only encode lower affinity
binding to 25OHD but also appear to circulate at lower
concentrations. In this setting, relatively low levels of total serum
25OHD may support relatively high levels of free 25OHD. By
contrast, a high affinity form of DBP would produce relatively low
free 25OHD. The latter may be important in ethnic groups such
as Africans and African-Americans known to exhibit a higher
prevalence of high affinity GC1F/1F DBP [11], where serum
levels of 25OHD are commonly low due to darker skin
pigmentation and impaired UV-light-induced epidermal synthesis
of vitamin D. Under these conditions the eSS model would predict
extremely low levels of free 25OHD. Thus, the eSS model may
help to evaluate the efficacy of vitamin D repletion strategies by
examining both free 25OHD and total 25OHD. Consequently,
optimization of vitamin D status in patients with high affinity DBP
or high DBP concentrations may require higher levels of
supplemental vitamin D than patients with low affinity/low
concentration DBP.
The iSS model was developed to further clarify the functional
biological impact of DBP-derived variations in free 25OHD. Data
in Table 5 show clearly that in the absence of any immune stimulus,
there is likely to be very little cathelicidin expression in vivo,
irrespective of vitamin D status or DBP genotype. In vivo, vitamin D-
mediated induction of cathelicidin is only observed when immune
stimulation is assumed to result in a 5-fold induction of VDR and
10-fold induction of CYP27B1. However, this effect is much more
pronounced for low affinity forms of DBP underlining the
importance of DBP as an important factor in defining the efficacy
of vitamin D-induced antibacterial activity both in vitro and in vivo.
The current model does not take into consideration activity of the
vitamin D catabolic enzyme 24-hydroxylase (CYP24A1), which
may attenuate the activity of 25OHD and 1,25(OH)2D by
catabolizing these metabolites [28,29]. Our model was based on
in vitro data after 6 hours (Figure 3) where the level of protein
expression and enzyme catalytic activity for CYP24A1 is likely to be
limited. Another consideration is that the presence of splice variant
forms of CYP24A1 [30] that result in catalytically inactive protein
may further diminish the impact of 24-hydroxylase activity during
the brief duration of immune activated intracrine-driven CAMP
expression.
The eSS and iSS mathematical models described in this paper
suggest a potential revision of parameters used to define adequate
and inadequate vitamin D status. However, the models were also
designed to help shed light on the basic mechanisms for vitamin D
action. In particular, the affinity of DBP for inactive 25OHD
relative to active 1,25(OH)2D was used to address a key unresolved
question concerning effects of vitamin D metabolites, such as the
induction of innate antibacterial activity. Namely, is intracrine
metabolism of 25OHD the most effective way for vitamin D to
enhance innate immunity or can endocrine levels of 1,25(OH)2D
achieve the same action? Data shown in Table 6 suggest that
intracrine metabolism is a far more effective way of inducing
monocyte-macrophage CAMP expression relative to the actions of
systemic 1,25(OH)2D. Clearly these are data designed for a
particular cell type and one specific response to vitamin D.
However, given that we have seen similar in vitro induction of
CAMP in other cell types [17], it is tempting to conclude that
similar intracrine pathways will be the optimal mechanism for
vitamin D responses at many extra-skeletal sites. This is important
given that serum 25OHD levels reflect changes in vitamin D status
and may, in turn, affect vitamin D-directed biological activity in
many peripheral tissues independent of 1,25(OH)2D.
Any attempt at mathematical modeling is constrained by
assumptions and these models assume the so-called ‘free hormone
hypothesis’ that has been proposed as a general mechanism for the
cellular uptake of steroid-like molecules because they are highly
lipophilic and therefore have the potential to passively diffuse
across cell membranes [21,31]. However, it is important to
recognize that in some circumstances vitamin D and its
metabolites utilize other mechanisms. For instance, in renal
proximal tubule cells, uptake of 25OHD and subsequent
conversion to 1,25(OH)2D involves endocytosis of DBP via the
megalin and cubilin receptors [15,32]. This process is fundamental
to the generation of circulating, endocrine levels of 1,25(OH)2D
and provides an explanation for the recent genome-wide
association studies of a white European cohort which showed
that lower affinity forms of DBP are associated with lower
circulating levels of 25OHD [33,34]. The conclusion from these
data is that 25OHD bound to lower affinity forms of DBP is less
readily reabsorbed into the proximal tubules and is thus excreted
more easily. Additionally, a similar DBP-megalin-mediated
endocytosis of 25OHD has also been described for breast
epithelial cells [35,36]. Thus, the ‘free hormone hypothesis’ we
incorporated into the eSS model is not necessarily universal.
Although data in this study are focused on non-classical actions
of 25OHD, these models could also be applied to cell types
engaged in classical actions. Preliminary in vitro data (Figure S1)
for 25OHD and 1,25(OH)2D mediated induction of osteocalcin
mRNA expression in MG-63 osteoblastic bone cells were
compared with mathematically predicted values. Data suggests
that the model used for adherent monocytes can be utilized in a
different cellular context although this requires modification of
some VDR and CYP27B1 dependent parameters. Thus, the
model may be useful in studying vitamin D action in a variety of
settings. For example, the action of synthetic vitamin D analogs
could be modeled where it has been shown that their biological
activities could be influenced by their differing affinities to DBP
and VDR [37]. Finally, we anticipate that the iSS model will be
useful in comparing predicted data with experimental observations
from wild type and DBP knockout mice. It is not possible to apply
our current cathelicidin readout to mice because vitamin D-
mediate regulation of this gene is observed only in primates [38].
One study using the DBP knockout mouse assessed macrophage
and neutrophil recruitment to a site thioglycolate injection showed
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that they were normal for this immune function despite their very
low serum levels of 25OHD [39]. How these mice respond to a
pathogenic challenge would be an important area for future
studies.
Materials and Methods
Cell culture
Ficoll isolated peripheral blood mononuclear cells (PBMCs)
derived from anonymous healthy donors that were screened
according to standard blood transfusion protocols were obtained
from the Center for AIDS Research Virology Core/BSL3 Facility
(supported by the National Institutes of Health award AI-28697
and by the UCLA AIDS Institute and the UCLA Council of
Bioscience Resources). Briefly, monocytes were enriched by
adherence by incubating 2.56106 PBMCs per well in 24-well
plates for 2 hours in Macrophage Serum Free Media (M-SFM,
Invitrogen, Carlsbad, CA). Non-adherent cells were removed by
washing with serum-free (SF) RPMI and remaining cells then
cultured overnight in RPMI with 10% human AB serum (Omega,
Tarzana, CA) supplemented with GM-CSF (10 U/ml; graciously
provided by Dr. Modlin. UCLA, Los Angeles, CA). After
overnight incubation, cells were washed with SF RPMI and then
incubated with RPMI+5% human AB serum (Omega, Tarzana,
CA) with varying amounts of 25OHD3 (10–300 nM),
1,25(OH)2D3 (0.04–12 nM) (Biomol, Plymouth Meeting, PA) or
with vehicle (0.2% ethanol) for 6 hrs. Figure 3 represented results
obtained from triplicate qPCR reactions performed on RNA
isolated from each well of dose response culture of adherent
monocytes from one donor. The general shape of the curve was
typical of dose responses but specific values to guide mathematical
model fitting was based on this specific assay run.
RNA Isolation and Quantitative Real-Time PCR
RNA was isolated by Trizol (Invitrogen, Carlsbad, CA)
extraction and cDNA was synthesized by Super Script Reverse
Transcriptase III (Invitrogen, Carlsbad, CA) according to manu-
facturer protocol utilizing random primers. Q-PCR analysis was
performed on a Stratagene MX-3005P instrument utilizing Taq-
Man system reagents from Applied Biosystems (Foster City, CA).
Specifically, we utilized FAM-labeled TaqMan Gene Expression
Assay probe/primer Hs00189038_m1 (CAMP) in conjunction with
VIC/MGB Probe/Primer Eukaryotic 18S rRNA Endogenous
Control (part number 4319413E) as the internal calibrator. All
cDNAs were amplified under the following conditions: 50uC for
2 min; 95uC for 10 min followed by 45 cycles of 95uC for 15 sec
and 60uC for 1 min. Results were reported as DD Ct values (DCt
value for vehicle-treated control – DCt for treated sample).
Mathematical Modeling
Extracellular steady state (eSS) free-ligand
modeling. The free/bound ligand-binding protein model
shown in Figure 1 (black reactions) was described previously with
mathematical equations for an arbitrary number of ligands and
binding proteins [22] and specifically for 25OHD and 1,25(OH)2D
binding to DBP and Albumin [9,10,23]. In general the buffering
reactions follow
vizbj
kz
ij
cij
cij
k{
ij
vizbj
where vi are ligands, bj are binding proteins, and cij are the
complexes of ligands and binding proteins which form at the rate k+ij
and dissociate at the rate k2ij. For our system in the extracellular
space vi M {25OHD, 1,25(OH)2D} are the free vitamin Dmetabolites,
and the bj M {DBPk, DBPl, Albumin} are the binding proteins where
we solve the system anew for each homo/heterogeneous genotype
pair (k,l), k,l M {GC1F, GC1S, GC2}. In steady state, free vitamin D
levels are described by the system of coupled non-linear algebraic
equations for each vitamin D metabolite
Vi~vizvi
X
j
Bj
Kijz
X
i
vi
ðM1Þ
where Vi and Bj represent total vi and bi, respectively, in free and
bound forms. Kij= k
2
ij/k
+
ij is the dissociation constant for vi binding
to bj. The different affinities [13] and expression levels of DBP
genotypes [12] and other biochemical parameters [9,10] are
described in Table 1. The equations in (M1) constitute the eSS
model. The results of the eSS model for increasing levels of 25OHD
or 1,25(OH)2D are shown in Figure 2.
Intracellular steady state (iSS) model. The intracellular
reactions shown in Figure 1 (gray reactions) describe the
incorporation of the actions of CYP27B1 and VDR in the cell
acting upon and responding to the ligands made available by DBP
and Albumin in the blood or general extracellular environment in
Figure 1 (black reactions) and calculated by the eSS model.
Because the blood volume in vivo or extracellular volume in vitro is
much larger than the intracellular volume (16106 fold for
monocytes in blood), we assume the extracellular levels of free
vitamin D, vo, are little affected by intracellular dynamics.
However, vo acts as a source for the intracellular levels of free
vitamin D, vc. Consequently, in addition to the extracellular free
levels (endocrine) we can add the intracellular levels created by
balancing free diffusion of vitamin D across the membrane and the
dynamics of CYP27B1 action (intracrine). The intracellular
component for 25OHD, vc1, then follows from solving for the
unique solution of the nonlinear algebraic equation
0~d vo1{v
c
1
 
{kcatYT
vc1
vc1zKm
ðM2aÞ
where v o1 has been fixed from solving (M1) and we assume the
Michaelis-Menten form for enzyme kinetics with unitary Hill
coefficient and Michaelis-Menten constant, Km. The permeability
of a monocyte to either 25OHD or 1,25(OH)2D is given by the
constant d and the maximal rate of enzymatic conversion is given
by the total amount of CYP27B1, YT, times the catalytic rate, kcat.
From the solution to equation (M2a), we calculate the free level of
intracellular 1,25(OH)2D as
vc2~v
o
2z
1
d
kcatYT
vc1
vc1zKm
ðM2bÞ
where v o2 has also been fixed from solving (M1). The equations
(M2a) and (M2b) along with the output of CAMP (described
below) constitutes the iSS model. Variables are shown in Table 3
and parameters in Table 4 respectively.
Modeling CAMP transactivation. We treat the final
production of CAMP as a competitive process between VDR
bound 1,25(OH)2D and VDR bound 25OHD binding to CAMP-
VDRE-DNA (proximal promoter) resulting in CAMP-mRNA
transcripts and CAMP itself. We normalize maximal production to
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1 plus basal levels (i.e. g=1) with the level of CAMP is given by
CAMP~g o1zo2ð ÞzCAMP0
where o1 and o2 are the fractions of active transcription complexes
containing 25OHD-VDR and 1,25(OH)2D-VDR, respectively, g
is the net rate of transcription and translation of CAMP relative to
the rate of CAMP-mRNA and CAMP degradation, and CAMP0 is
the basal CAMP level. The VDR bound to 25OHD, r1, and VDR
bound to1,25(OH)2D, r2, are given as functions of free 25OHD,
vc1, and free 1,25(OH)2D, v
c
2, while the active fractions of the
CAMP-VDRE-DNA, o1 and o2 are given as functions of r1 and r2.
r1~
Kr2
ppvc
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:
VDR related parameters
The number of VDR molecules per cell was set at 3000 [40];
thus, basal VDR concentration was calculated to be 1.2 nM
assuming monocytes were spherical with a diameter of 20 mm
[41]. VDR bound 1,25(OH)2D with affinity constant 1/
Kr2=1610
10 M21 [42] and we estimated 25OHD bound VDR
with affinity constant 1/Kr1=2610
7 M21 which is 500-fold
weaker [43]. For this modeling effort, a dissociation constant
Kcc2=1610
210 M was used based on the reported value from
VDR/1,25(OH)2D binding to VDRE oligonucleotide probes in
electrophoretic mobility shift assays [44]. Affinity for actual
VDRE targets in chromatin might differ. We assumed that
VDR/25OHD was 10-fold less able to bind VDRE
(Kcc1=1610
29 M). Additionally, once VDR/25OHD/VDRE
complexes were formed, we assumed they were equally as
effective in yielding complete transcripts compared to VDR/
1,25(OH)2D/VDRE complexes. Thus, the key determinant of
sensitivity is the much lower affinity of VDR for 25OHD
compared to 1,25(OH)2D.
We assume the potential for cooperativity of free 25OHD or
1,25(OH)2D in binding to VDR and in VDR/25OHD or VDR/
1,25(OH)2D in binding to VDRE. We find that a power of 2
(pp=2) in 1,25(OH)2D binding to VDR and a power of 2 (p=2) in
VDR/1,25(OH)2D binding to VDRE to be optimal cooperativity
constraining other parameters. We also find that while coopera-
tivity of 25OHD binding to VDR does not seem important
(mm=1), there appears to be useful cooperativity of VDR/
25OHD binding to VDRE (m=2). We do note that while m=2
works well for both the monocyte and MG-63 cell data, for MG-
63 cells m=1 has a better fit at low 25OHD while keeping the
model within standard deviation bounds at higher 25OHD levels
(data not shown). While o1 does not impact CAMP production in
the present study, we retain the term in the model for potential
interest in 25OHD rescue of vitamin D dependent activation in
the context of CYP27B1 knock-out mice [45].
CYP27B1 related parameters
The rate of CYP27B1 activity in mitochondria of living cells is
unknown but CYP27B1 enzymatic activity has been measured in
reconstitution studies with artificial vesicles [46]; thus, we have
assumed an enzyme rate of 0.1 mM/hr consistent with that
report. The amount of CYP27B1 in cells is also not known.
However, based on mathematical fitting of our in vitro
experimental data and an assumed CYP27B1 rate of 0.1 mM/
hr, we estimated the basal amount of CYP27B1 to be 0.1 nM.
Km of CYP27B1 was set at 1 mM based on reports measuring the
Km between 0.38–2.7 mM [29,47,48,49]. We also assumed the
potential for cooperativity in enzymatic conversion of 25OHD to
1,25(OH)2D but cooperativity in 25OHD binding to CYP27B1
then also requires 25OHD/VDR affinity to VDRE to be greater
than that of 1,25(OH)2D/VDR to compensate and fit the in vitro
data. This would imply that 25OHD was driving CAMP
production rather than 1,25(OH)2D, and so coupled with the
lack of evidence for CYP27B1 using cooperativity we reject
enzyme cooperativity in this case.
Computational Solution
The eSS and iSS models were solved using Matlab (Mathworks,
2009) and are available upon request of the authors.
Supporting Information
Figure S1 Comparison of iSS-predicted effects of
25OHD or 1,25(OH)2D on MG-63 osteoblast expression
of osteocalcin with observed in vitro dose responses.
MG-63 were incubated for 6 hrs in media containing 2% serum
with doses of (A) 25OHD (0–200 nM) and (B) 1,25(OH)2D (0–
20 nM) and osteocalcin expression (DDCt) was determined by
qPCR. In each case, experimental data are indicated by blue dots
and error bars (6 SD) and reflect two biological treatment
replicates and three qPCR determination replicates of each
biological sample. Dashed lines indicate data produced by the
iSS mathematical model using monocyte parameters. Dotted lines
indicate model after adjustment of parameters to permit fitting to
1,25(OH)2D experimental data. Black lines indicate model after
adjustment of parameters to permit fitting to 25OHD experimen-
tal data. Please note that dashed and black lines are the same in (B)
but not (A). For the purpose of this modeling, DBP was
represented by the GC1F/1F allelic combination.
(TIF)
Text S1 Material and Methods for Figure S1.
(DOC)
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